

# Simon Mantha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9229507/publications.pdf>

Version: 2024-02-01

37  
papers

1,133  
citations

623734

14  
h-index

477307

29  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1649  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy After Venous Interventions: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 175-187.	2.2	8
2	Romiplostim for chemotherapyâ€induced thrombocytopenia: Efficacy and safety of extended use. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12701.	2.3	6
3	Cancer genetic alterations and risk of venous thromboembolism. Thrombosis Research, 2022, 213, S29-S34.	1.7	3
4	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113.	1.4	57
5	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
6	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
7	Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naïve acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2497-2501.	1.3	1
8	Prediction of COVID-19 Mortality in Patients with Cancer. Blood, 2020, 136, 29-30.	1.4	0
9	Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project. Blood, 2020, 136, 18-19.	1.4	0
10	Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism. Blood, 2020, 136, 37-37.	1.4	1
11	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
12	Bleeding Disorders Associated with Cancer. Cancer Treatment and Research, 2019, 179, 191-203.	0.5	5
13	Rivaroxaban treatment of cancerâ€associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 349-356.	2.3	29
14	Extended Mutational Profiling By MSK-IMPACT™ Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. Blood, 2019, 134, 633-633.	1.4	1
15	Anticoagulation in the Patient with Cancer. , 2018, , 425-440.		1
16	Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S98-S102.	1.7	16
17	Hypofibrinogenemia and Disseminated Intravascular Coagulation Rarely Complicate Treatment-Naive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1217-1217.	1.4	0
18	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	1.4	78

#	ARTICLE	IF	CITATIONS
19	Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. <i>American Journal of Cardiology</i> , 2017, 120, 213-217.	1.6	44
20	Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 489-493.	2.1	16
21	Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. <i>American Journal of Hematology</i> , 2017, 92, E9-E10.	4.1	36
22	Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 166-171.	2.1	84
23	What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?. <i>Current Opinion in Hematology</i> , 2016, 23, 121-126.	2.5	52
24	Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer. <i>Blood</i> , 2016, 128, 2621-2621.	1.4	2
25	Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Treatment of Cancer-Associated Thrombosis. <i>Blood</i> , 2016, 128, 2619-2619.	1.4	1
26	Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 208.e1-208.e4.	1.3	13
27	Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 155-165.	2.1	66
28	Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Thrombosis. <i>Blood</i> , 2015, 126, 2068-2068.	1.4	2
29	Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study. <i>Blood</i> , 2015, 126, 429-429.	1.4	2
30	Safe and Effective Use of Rivaroxaban for Treatment of Cancer-Associated Venous Thromboembolic Disease: A Quality Improvement Initiative. <i>Blood</i> , 2015, 126, 431-431.	1.4	3
31	Outcomes of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications. <i>Blood</i> , 2015, 126, 1112-1112.	1.4	0
32	Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 76-79.	2.1	13
33	New Avenues for Anticoagulation in Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 68-77.	4.7	21
34	Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 155-162.	2.1	1
35	An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 476-484.	3.4	140
36	Progestin-Only Contraceptives and the Risk of Venous Thromboembolism: Systematic Review and Meta-Analysis. <i>Blood</i> , 2011, 118, 3344-3344.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Determinants of Intracranial Hemorrhage Incidence in Patients on Oral Anticoagulation Followed at the Lahey Clinic.. Blood, 2010, 116, 1101-1101.	1.4	0